46256 Federal Register / Vol. 86, No. 157 / Wednesday, August 18, 2021 / Notices 

burden of maintaining records and 

providing disclosures to consumers. All 

comments must be received on or before 

October 18, 2021. 

You can file a comment online or on 

paper. For the FTC to consider your 

comment, we must receive it on or 

before October 18, 2021. Write ‘‘Pay-PerCall Rule; PRA Comment: FTC File No. 

P072108’’ on your comment. Your 

comment—including your name and 

your state—will be placed on the public 

record of this proceeding, including the 

https://www.regulations.gov website. 

Due to the public health emergency in 

response to the COVID–19 outbreak and 

the agency’s heightened security 

screening, postal mail addressed to the 

Commission will be subject to delay. We 

encourage you to submit your comments 

online through the https://

www.regulations.gov website. 

If you prefer to file your comment on 

paper, write ‘‘Pay-Per-Call Rule; PRA 

Comment: FTC File No. P072108’’ on 

your comment and on the envelope, and 

mail your comment to the following 

address: Federal Trade Commission, 

Office of the Secretary, 600 

Pennsylvania Avenue NW, Suite CC– 

5610 (Annex J), Washington, DC 20580; 

or deliver your comment to the 

following address: Federal Trade 

Commission, Office of the Secretary, 

Constitution Center, 400 7th Street SW, 

5th Floor, Suite 5610 (Annex J), 

Washington, DC 20024. If possible, 

submit your paper comment to the 

Commission by courier or overnight 

service. 

Because your comment will become 

publicly available at https://

www.regulations.gov, you are solely 

responsible for making sure that your 

comment does not include any sensitive 

or confidential information. In 

particular, your comment should not 

include any sensitive personal 

information, such as your or anyone 

else’s Social Security number; date of 

birth; driver’s license number or other 

state identification number, or foreign 

country equivalent; passport number; 

financial account number; or credit or 

debit card number. You are also solely 

responsible for making sure that your 

comment does not include any sensitive 

health information, such as medical 

records or other individually 

identifiable health information. In 

addition, your comment should not 

include any ‘‘trade secret or any 

commercial or financial information 

which . . . . is privileged or 

confidential’’—as provided by Section 

6(f) of the FTC Act, 15 U.S.C. 46(f), and 

FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)— 

including in particular competitively 

sensitive information such as costs, 

sales statistics, inventories, formulas, 

patterns, devices, manufacturing 

processes, or customer names. 

Comments containing material for 

which confidential treatment is 

requested must be filed in paper form, 

must be clearly labeled ‘‘Confidential,’’ 

and must comply with FTC Rule 4.9(c). 

In particular, the written request for 

confidential treatment that accompanies 

the comment must include the factual 

and legal basis for the request, and must 

identify the specific portions of the 

comment to be withheld from the public 

record. See FTC Rule 4.9(c). Your 

comment will be kept confidential only 

if the General Counsel grants your 

request in accordance with the law and 

the public interest. Once your comment 

has been posted publicly at 

www.regulations.gov, we cannot redact 

or remove your comment unless you 

submit a confidentiality request that 

meets the requirements for such 

treatment under FTC Rule 4.9(c), and 

the General Counsel grants that request. 

The FTC Act and other laws that the 

Commission administers permit the 

collection of public comments to 

consider and use in this proceeding, as 

appropriate. The Commission will 

consider all timely and responsive 

public comments that it receives on or 

before October 18, 2021. For 

information on the Commission’s 

privacy policy, including routine uses 

permitted by the Privacy Act, see 

https://www.ftc.gov/site-information/ 

privacy-policy. 

Josephine Liu, 

Assistant General Counsel for Legal Counsel. 

[FR Doc. 2021–17662 Filed 8–17–21; 8:45 am] 

BILLING CODE 6750–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2021–0089] 

Advisory Committee on Immunization 

Practices (ACIP) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting and request 

for comment. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC), announces the 

following meeting of the Advisory 

Committee on Immunization Practices 

(ACIP). This meeting is open to the 

public. The meeting will be webcast live 

via the World Wide Web. A notice of 

this ACIP meeting has also been posted 

on CDC’s ACIP website at: http://

www.cdc.gov/vaccines/acip/index.html. 

In addition, CDC has sent notice of this 

ACIP meeting by email to those who 

subscribe to receive email updates about 

ACIP. 

DATES: The meeting will be held on 

August 24, 2021, from 10:00 a.m. to 5:00 

p.m., EDT (dates and times subject to 

change), see the ACIP website for 

updates: http://www.cdc.gov/vaccines/ 

acip/index.html. The public may submit 

written comments from August 18, 2021 

through August 24, 2021. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2021– 

0089 by any of the following methods: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

MS H24–8, Atlanta, Georgia 30329– 

4027, Attn: August 24, 2021 ACIP 

Meeting. 

Instructions: All submissions received 

must include the Agency name and 

Docket Number. All relevant comments 

received in conformance with the 

https://www.regulations.gov suitability 

policy will be posted without change to 

https://www.regulations.gov, including 

any personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

https://www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Stephanie Thomas, ACIP Committee 

Management Specialist, Centers for 

Disease Control and Prevention, 

National Center for Immunization and 

Respiratory Diseases, 1600 Clifton Road 

NE, MS–H24–8, Atlanta, Georgia 30329– 

4027; Telephone: (404) 639–8367; 

Email: ACIP@cdc.gov. 

SUPPLEMENTARY INFORMATION: In 

accordance with 41 CFR 102–3.150(b), 

less than 15 calendar days’ notice is 

being given for this meeting due to the 

exceptional circumstances of the 

COVID–19 pandemic and rapidly 

evolving COVID–19 vaccine 

development and regulatory processes. 

A notice of this ACIP meeting has also 

been posted on CDC’s ACIP website at: 

http://www.cdc.gov/vaccines/acip/ 

index.html. In addition, CDC has sent 

notice of this ACIP meeting by email to 

those who subscribe to receive email 

updates about ACIP. 

Purpose: The committee is charged 

with advising the Director, CDC, on the 

use of immunizing agents. In addition, 

under 42 U.S.C. 1396s, the committee is 

mandated to establish and periodically 


jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 157 / Wednesday, August 18, 2021 / Notices 46257 

review and, as appropriate, revise the 

list of vaccines for administration to 

vaccine-eligible children through the 

Vaccines for Children (VFC) program, 

along with schedules regarding dosing 

interval, dosage, and contraindications 

to administration of vaccines. Further, 

under provisions of the Affordable Care 

Act, section 2713 of the Public Health 

Service Act, immunization 

recommendations of the ACIP that have 

been approved by the Director of the 

Centers for Disease Control and 

Prevention and appear on CDC 

immunization schedules must be 

covered by applicable health plans. 

Matters To Be Considered: The agenda 

will include discussions on additional 

doses of COVID–19 vaccine, including 

booster doses. Agenda items are subject 

to change as priorities dictate. For more 

information on the meeting agenda visit 

https://www.cdc.gov/vaccines/acip/ 

meetings/meetings-info.html. 

Meeting Information: The meeting 

will be webcast live via the World Wide 

Web; for more information on ACIP 

please visit the ACIP website: http://

www.cdc.gov/vaccines/acip/index.html. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. Please note that comments 

received, including attachments and 

other supporting materials, are part of 

the public record and are subject to 

public disclosure. Comments will be 

posted on https://www.regulations.gov. 

Therefore, do not include any 

information in your comment or 

supporting materials that you consider 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 

CDC will review all submissions and 

may choose to redact, or withhold, 

submissions containing private or 

proprietary information such as Social 

Security numbers, medical information, 

inappropriate language, or duplicate/ 

near duplicate examples of a mass-mail 

campaign. CDC will carefully consider 

all comments submitted into the docket. 

Written Public Comment: Written 

comments must be received on or before 

August 24, 2021. 

Oral Public Comment: This meeting 

will include time for members of the 

public to make an oral comment. Oral 

public comment will occur before any 

scheduled votes including all votes 

relevant to the ACIP’s Affordable Care 

Act and Vaccines for Children Program 

roles. Priority will be given to 

individuals who submit a request to 

make an oral public comment before the 

meeting according to the procedures 

below. 

Procedure for Oral Public Comment: 

All persons interested in making an oral 

public comment at the August 24, 2021, 

ACIP meeting must submit a request at 

http://www.cdc.gov/vaccines/acip/ 

meetings/ no later than 11:59 p.m., EDT, 

August 22, 2021, according to the 

instructions provided. 

If the number of persons requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

time, CDC will conduct a lottery to 

determine the speakers for the 

scheduled public comment session. 

CDC staff will notify individuals 

regarding their request to speak by email 

by 12:00 p.m., EDT, August 23, 2021. To 

accommodate the significant interest in 

participation in the oral public 

comment session of ACIP meetings, 

each speaker will be limited to 3 

minutes, and each speaker may only 

speak once per meeting. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–17808 Filed 8–16–21; 4:15 pm] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Award of a Single-Source 

Grant To Fund Task Force for Global 

Health, Inc. 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS) announces the 

award of approximately $47,000,000 in 

COVID–19 funding with an expected 

total funding of $100,000,000 over a 

five-year period to the Task Force for 

Global Health to expand the influenza 

and COVID–19 vaccine coverage in lowand middle-income countries. 

DATES: The period for this award will be 

September 30, 2021 through September 

29, 2026. 

FOR FURTHER INFORMATION CONTACT: 

Archana Kumar, National Center for 

Immunization and Respiratory Diseases, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS– 

H24–8, Atlanta, GA 30329, Telephone: 

800–232–6348, E-Mail: eocevent445@

cdc.gov. 

SUPPLEMENTARY INFORMATION: The 

single-source award will introduce and/ 

or expand influenza vaccine programs, 

contribute to evidence base for 

influenza control and prevention, and 

leverage efforts to deploy pandemic 

vaccines to low- and middle-income 

countries. 

The Task Force for Global Health will 

be awarded as a single-source because of 

their specific experience collaborating 

with multiple partners in facilitating the 

use of influenza vaccines in low- to 

middle-income countries and in 

developing local and global evidence 

base for sustained use of lifesaving 

vaccines since 2014. The Task Force for 

Global Health is uniquely qualified to 

support countries to plan for, 

implement and evaluate COVID–19 

vaccination programs since they are 

currently working with the same risk 

groups using established tools and 

platforms under an existing cooperative 

agreement. The Task Force for Global 

Health leads the Partnership for 

Influenza Vaccine Introduction which 

includes ministries of health from 15 

countries, private industry, and the 

United Nations International Children’s 

Emergency Fund. This Partnership 

creates sustainable, seasonal influenza 

vaccination programs in the targeted 

countries, works with the World Health 

Organization to prepare for pandemic 

influenza, and supports countries’ 

efforts to control and prevent seasonal 

outbreaks. 

Summary of the Award 

Recipient: The Task Force For Global 

Health. 

Purpose of the Award: The purpose of 

award is to expand the use of influenza 

and COVID–19 vaccines in low- and 

middle-income countries (LMICs), 

support influenza vaccine introduction 

through a public-private partnership, 

establish an evidence base for global 

vaccine introduction decisions, and 

leverage this partnership to support 

readiness for and deployment of future 

pandemic vaccines. The recipient will 

be expected to assist partner countries 


jbell on DSKJLSW7X2PROD with NOTICES